Cisterna MagnaUrokinase-Type Plasminogen ActivatorStrokeBrain IschemiaFibrinolytic AgentsTissue Plasminogen ActivatorInfusions, IntravenousThrombolytic TherapyAcute DiseaseReceptors, Urokinase Plasminogen ActivatorCerebral HemorrhageTreatment OutcomeInfusions, Intra-ArterialCerebrovascular DisordersCerebral InfarctionInfusions, ParenteralTime FactorsIntracranial ThrombosisIntracranial HemorrhagesMechanical ThrombolysisInfarction, Middle Cerebral ArteryTomography, X-Ray ComputedProspective StudiesThrombectomyInfusion PumpsIschemic Attack, TransientReperfusionCerebral AngiographyCerebral RevascularizationRisk FactorsInjections, Intra-ArterialBrain InfarctionRetrospective StudiesPredictive Value of TestsReproducibility of ResultsObserver VariationInjections, IntravenousSeverity of Illness IndexMagnetic Resonance ImagingIntracranial EmbolismFollow-Up StudiesSuperficial Back MusclesNeuroprotective AgentsCerebrovascular CirculationDiffusion Magnetic Resonance ImagingBrainMagnetic Resonance AngiographyIntracranial Arterial DiseasesAnticoagulantsCohort StudiesRecovery of FunctionDouble-Blind MethodMiddle Cerebral ArteryEmbolectomyCerebral ArteriesUltrasonography, Doppler, TranscranialSensitivity and SpecificityPerfusion ImagingRecurrencePrognosisPlatelet Aggregation InhibitorsHeparinoidsBlood PressureDose-Response Relationship, DrugRegistriesBrain EdemaOdds RatioReceptors, Cell SurfaceEmergency Medical ServicesAdministration, IntravenousIschemiaPlasminogen ActivatorsInfarction, Anterior Cerebral ArteryNeurologic ExaminationMultivariate AnalysisEndovascular ProceduresIntracranial ArteriosclerosisCase-Control StudiesFibrinolysinComorbidityAtrial FibrillationPlasminogenRecombinant ProteinsIncidenceDrug Administration ScheduleLogistic ModelsFibrinolysisAge FactorsRandomized Controlled Trials as TopicBiological MarkersIntracranial Embolism and ThrombosisAspirinCerebral Arterial DiseasesHemodilutionPhlebitisPilot ProjectsRiskInfusion Pumps, ImplantableNadroparinHemorrhage